Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Mucosal vaccines are receiving increasing interest both for protecting against infectious diseases and for inducing therapeutic immune responses to treat non-infectious diseases. However, the mucosal barriers of the lungs, gastrointestinal tract, genitourinary tract, nasal, and oral tissues each present unique challenges for constructing efficacious vaccines. Vaccination through each of these mucosae requires transport through the mucus and across specialized epithelia to reach tissue-specific immune cells and lymphoid structures, necessitating finely tuned and multifunctional strategies. Serving as inspiration for mucosal vaccine design, pathogens have evolved elaborate, diverse, and multipronged approaches to penetrate and infect mucosae. This review is focused on biomaterials-based strategies, many inspired by pathogens, for designing mucosal vaccine platforms. Passive and active technologies are discussed, along with the microbial processes that they seek to mimic.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1039/d2bm01694j | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Immunoenhancing effects of Gynostemma Pentaphyllum Extract on mucosal immunity against porcine epidemic diarrhea virus.
Front Vet Sci
August 2025
College of Veterinary Medicine, China Agricultural University, Beijing, China.
Introduction: This study investigated the mucosal immunoadjuvant effects of Gynostemma Pentaphyllum Extract (Gynostemma P.E), the bioactive constituents of , against porcine epidemic diarrhea virus (PEDV).
Methods: Twenty-four mice were randomly divided into four groups: a negative control group (intranasal administration of antigen only), a Gynostemma P.
Efficacy of an intranasally administered live attenuated PRRSV-2 vaccine against challenge with a highly virulent PRRSV-1 strain.
Front Vet Sci
August 2025
Laboratorio Avi-Mex, S. A. de C. V., Ciudad de Mexico, Mexico.
Introduction: The emergence of highly virulent strains of the porcine reproductive and respiratory syndrome virus has driven the need for new vaccines. This study evaluates the efficacy of an intranasal (IN) vaccine composed of a naturally attenuated PRRSV-2 isolate, compared to a commercially available intramuscularly administered (IM) PRRSV-1 vaccine, against a heterologous challenge with a highly virulent PRRSV-1 strain (R1).
Methods: Sixty-eight PRRSV-naïve pigs were divided into four groups: two non-vaccinated controls (NV/NCh, NV/Ch), one IM-vaccinated with a PRRSV-1 MLV (Por), and one intranasally (IN)-vaccinated with the PRRSV-2 vaccine (IL).
Cord blood innate-like T cell responses in neonates born to healthy women and women living with HIV.
Front Immunol
September 2025
Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, United States.
Innate-like T cells (ILT), including γδ T cells (Vδ2s), Natural Killer T cells (NKTs) and Mucosal-associated Invariant T cells (MAITs), integrate innate and adaptive immunity, playing important roles in homeostatic conditions as well as during infection or inflammation. ILT are present on both sides of the fetal-maternal interface, but our knowledge of their phenotypical and functional features in neonates is limited. Using spectral flow cytometry we characterized cord blood ILT in neonates born to healthy women and women living with HIV.
View Article and Find Full Text PDFOptimizing mucosal vaccination: Exploiting Lactobionic acid-modified chitosan for superior gene delivery systems.
Int J Biol Macromol
September 2025
CNC-UC - Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, 3004-504, Portugal; CIBB - Center for Innovative Biomedicine and Biotechnology, University of Coimbra, Coimbra, 3004-504, Portugal; Faculty of Pharmacy, University of Coimbra, Coimbra, 3000-548, Portugal. Electronic a
The increasing prevalence of respiratory disorders highlights the urgent need for effective mucosal vaccines that elicit targeted immune responses at pathogen entry sites. However, the advancement of mucosal vaccines is limited by challenges in antigen delivery and overcoming mucosal immune tolerance. In this study, we developed a gene delivery platform using chitosan functionalized with lactobionic acid (LA) to enhance targeting of antigen-presenting cells and to form stable DNA polyplexes with high transfection efficiency.
View Article and Find Full Text PDFOral Immunization with Recombinant Saccharomyces cerevisiae expressing TM1 of Mycoplasma gallisepticum induces Unique Specific Antibodies and Protective Immunity.
Microb Pathog
September 2025
School of Life Science, Liaoning University, Chongshanzhong-Lu No. 66, Shenyang, 110036, China. Electronic address:
Mycoplasma gallisepticum (MG) is one of the main pathogens causing chronic respiratory diseases in chickens, which seriously affects the sustainable and healthy development of the poultry industry and leading to heavy economic losses. Therefore, we developed a safe, efficient, convenient, and low-cost MG oral vaccine. The vaccine is based on a recombinant yeast surface display system to compensate for the shortcomings of existing vaccines.
View Article and Find Full Text PDF